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New York.Introduction
Implantable cardioverter-deﬁbrillators (ICDs) are a mainstay
of therapy for patients at risk for recurrent life-threatening
ventricular arrhythmias. As increasing numbers of patients
with ICDs are encountered in clinical practice, the rising
morbidity, mortality, and costs linked to cardiac implantable
electronic devices have been recognized.1,2 Without the
presence of indwelling transvenous leads, subcutaneous
ICDs (S-ICDs) offer a theoretical advantage over trans-
venous ICDs (TV-ICDs) by lowering the risk of systemic
infection and endocarditis. In 2 large registry studies, rates of
S-ICD–related infections over 2-year follow-up were 1.7%
and 4%.3,4 No cases of systemic infection were reported in
either study. Here, we report 2 separate cases of systemic
infection associated with S-ICDs referred to our institution
for further management within a 3-month period.
Case 1
A 55-year-old man with a history of ischemic cardiomyop-
athy with a left ventricular ejection fraction of 30%–35%,
status post coronary artery bypass grafting, insulin-
dependent diabetes mellitus, and end-stage renal disease
(ESRD) on hemodialysis underwent S-ICD implantation at
an outside institution for primary prevention ICD therapy.
Perioperative intravenous vancomycin and cefazolin and
postoperative oral cephalexin were given at the time of his
procedure. He developed a postoperative pocket hematoma.
During his follow-up 2 weeks later, he had continued
swelling with no drainage. He was scheduled for continuedKEYWORDS Subcutaneous implantable cardioverter-deﬁbrillator; Systemic
infection; Hematoma (Heart Rhythm Case Reports 2016;0:1–3)
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noted wound dehiscence with purulent discharge. He also
developed left eye pain, blurry vision, and conjunctival
erythema. He returned to his implanting institution where he
underwent successful S-ICD system explantation with
pocket washout and packing. Wound cultures were positive
for methicillin-resistant Staphylococus aureus, and he was
treated with vancomycin. Blood cultures were negative.
Transthoracic and transesophageal echocardiograms did
not demonstrate valvular vegetations. He presented to our
institution with persistent eye symptoms. A slit lamp
examination revealed a white mass extending through the
retina into the vitreous humor consistent with bacterial or
fungal endophthalmitis. Initially, he was given intravitreal
vancomycin and ceftazidime and intravenous voriconazole.
Visual acuity at that time was OS 20/200, and a repeat slit
lamp examination showed local vitritis overlying a white
retinal lesion. Despite the absence of vitreous cultures, it was
felt that the patient likely had methicillin-resistant S aureus
endophthalmitis. Voriconazole and ceftazidime were dis-
continued. Intravitreal antibiotics were changed to topical
antibiotics, and his vision improved to OS 20/60. He
was discharged on a 6-week course of vancomycin admin-
istered at hemodialysis. After his antibiotic course, he had
return to normal OS 20/20 vision with normal slit lamp
examination.Case 2
A 35-year-old woman with a history of ischemic cardiomy-
opathy with a left ventricular ejection fraction of 34%,
insulin-dependent diabetes mellitus, ESRD on hemodialysis,
and ventricular tachycardia underwent S-ICD implantation at
an outside institution for secondary prevention ICD therapy.
The device was implanted in a submuscular pocket under the
serratus anterior. The patient was treated with aspirin and
clopidogrel at the time of the procedure. Perioperative
intravenous cefazolin and postoperative oral cephalexin were
given at the time of her procedure. During her follow-up visitpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.08.014
Figure 2 Computed tomographic scan of the chest showing device pocket
infection. A rim-enhancing ﬂuid collection (11.4  5.1  10.1 cm)
surrounding the subcutaneous implantable cardioverter-deﬁbrillator genera-
tor is shown. A small pocket of air within the ﬂuid collection is also shown.
S-ICD ¼ subcutaneous implantable cardioverter-deﬁbrillator.
KEY TEACHING POINTS
 This case report describes 2 cases of systemic
infections due to subcutaneous implantable
cardioverter-deﬁbrillator (S-ICD) implantation.
 Both cases involved patients with end-stage renal
disease on hemodialysis and diabetes mellitus who
had pocket swelling soon after device
implantation.
 These cases highlight the importance of vigilance
for pocket-related complications soon after S-ICD
implantation. Early intervention for pocket
hematomas and infection may prevent progression
to systemic infection.
Heart Rhythm Case Reports, Vol 0, No 0, Month 201622 weeks after device implantation, the patient noted pain and
swelling. This was managed with observation, with a plan for
a follow-upvisit if symptoms worsened. The swelling and
pain improved but never completely resolved. Four months
later, she presented to our institution with progressive pain
and swelling around her device as well as by her subxiphoid
and sub-suprasternal notch incisions. On physical examina-
tion, swelling and tenderness around the device pocket were
noted. In addition, superﬁcial ulceration with purulent
discharge was noted at the prior subxiphoid incision site
(Figure 1). Warmth was palpated along the entire tract of the
S-ICD lead from the device pocket and along the sternal
region. Empiric vancomycin and piperacillin-tazobactam
were administered. Blood cultures drawn before the initia-
tion of antibiotics were positive for methicillin-sensitive S
aureus. The antibiotic regimen was changed to nafcillin. A
computed tomographic scan of the chest demonstrated a rim-
enhancing ﬂuid collection (11.4  5.1  10.1 cm) surround-
ing the S-ICD generator suspicious for abscess with inﬂam-
matory changes tracking along the ICD lead (Figure 2).
Transesophageal echocardiography did not reveal any valv-
ular vegetations. She underwent device extraction,Figure 1 Physical appearance of the chest before subcutaneous implan-
table cardioverter-deﬁbrillator system removal. Purulent drainage from the
subxiphoid incision is shown. There is moderate swelling by the device
pocket. The sub-suprasternal notch (superior) incision is intact, but erythema
is noted.debridement, and pocket irrigation with plastic surgery
assistance. More than 200 cm3 of purulent ﬂuid was removed
and sent for culture, which eventually grew out methicillin-
sensitive S aureus (Figure 3). All 3 wounds were left open
and packed. After a week of adequate healing, a wound
vacuum dressing was placed on the prior pocket incision.
The patient was discharged to a rehabilitation center with a
wearable external deﬁbrillator (LifeVest, Zoll Medical,
Chelmsford, MA) on 4 weeks of nafcillin therapy.
Discussion
Here, we present 2 patients who developed systemic
infections as a complication of S-ICD implantation. One
patient had bacterial endophthalmitis due to transient hem-
atogenous spread from his ICD pocket infection, and another
had documented bacteremia. Both patients had risk factors
for device infection, including ESRD requiring hemodialysis
as well as insulin-dependent diabetes mellitus. In addition,
both patients had swelling of their device pocket soon after
implantation consistent with pocket hematoma formation
and presented with systemic infection more than 3 months
after device implantation.
Without transvenous leads, S-ICDs offer potential advan-
tages over TV-ICD with respect to possibly decreased risks
of intravascular and systemic infections, lead dislodgment,
and transvenous lead implantation–associated complicationsFigure 3 Still image from the video recording during device explantation.
More than 200 cm3 of purulent ﬂuid was drained upon incision of the device
pocket site.
3Looser et al Systemic Infection and Subcutaneous ICDssuch as pneumothorax and cardiac perforation. Rates of S-
ICD implantation–related infections have been reported in
the range of 1.7%–4.1%.3,4 In comparison, rates of TV-ICD
infection between 0.6% and 1.7% over variable follow-up
have been reported.5–8 In the absence of prospective head-to-
head study data, comparisons of S-ICD and TV-ICD
infection rates using prospective and retrospective cohort
data are limited by differences in implantation techniques,
use of antibiotic prophylaxis, patient characteristics, and
follow-up time.
We have shown that S-ICD pocket infections can
progress to systemic infection. Both patients in our report
had risk factors of pocket hematoma, ESRD, and diabetes
that predisposed them for systemic infection. A meta-
analysis on transvenous cardiac implantable electronic
device infections found that pocket hematoma, ESRD, and
diabetes were associated with 8.5-fold, 8.7-fold, and 2-fold
increases in infection rates, respectively.9 The conﬂuence of
all these factors likely contributed to the systemic progres-
sion of infection in our 2 patients. In case 2, the patient
underwent device implantation receiving dual antiplatelet
therapy, which may have increased her likelihood of devel-
oping a hematoma. Moreover, she had a subserratus S-ICD
implant, which may have led to a delay in the recognition of
pocket hematoma and infection given its deep location. The
cases raise the question of whether early intervention with
hematoma evacuation could have prevented progression to
pocket infection with subsequent systemic involvement. In
our cases, the timing of diagnosis of systemic infection was 4
and 7 months after S-ICD implantation, which reﬂected the
prolonged duration of indolent pocket infection before the
onset of systemic infection. Given the clear link between
pocket hematomas and the risk of device infection, strategies
to reduce hematoma formation are critical.10 Given the size
and location of the device pocket required for S-ICDs,
careful attention to hemostasis is mandatory, especially
when using a submuscular approach. In addition, in case 2,
avoidance of clopidogrel (which was administered for a
remote history of coronary stents) may have helped prevent
pocket hematoma.
Of note, both patients in this report had ESRD requiring
hemodialysis. The relationship between systemic infections
in patients on hemodialysis with TV-ICDs has been well
established.11,12 Given the absence of transvenous leads, S-
ICDs have been suggested to be a preferable alternative to
TV-ICDs for patients on hemodialysis on the basis of limited
observational study data.13 It remains to be seen whether S-
ICDs would have lower long-term infection rates in compar-
ison to TV-ICDs in this high-risk population.
As more S-ICDs are implanted worldwide, especially in
younger patients and patients at higher risk for intravascular
infection, such as patients with ESRD, recognition of the
range of complications associated with S-ICDs is of para-
mount importance. Earlier intervention for pocket hematomas
found in the 2 patients described in this report may have led tothe avoidance of systemic infection. Although several reports
from S-ICD registries have reported success with conservative
management of suspected S-ICD infection without device
explantation,14,15 we believe that such an approach should
be considered with caution, especially in patients with
signiﬁcant comorbidities such as ESRD. Our report high-
lights the fact that the absence of transvenous leads does not
eliminate the risk of systemic infection from S-ICD
implantation. The results of prospective randomized trials
will be critical for assessing the superiority of S-ICDs in
reducing the long-term risks of serious systemic infection.
Improvements in operative technique, in operator experi-
ence, and in the recognition and management of S-ICD
implantation–related complications may result in better
long-term outcomes.References
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